Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 266
Filtrar
1.
Viruses ; 12(7)2020 07 07.
Artigo em Inglês | MEDLINE | ID: mdl-32646015

RESUMO

Standard precautions to minimize the risk of SARS-CoV-2 transmission implies that infected cell cultures and clinical specimens may undergo some sort of inactivation to reduce or abolish infectivity. We evaluated three heat inactivation protocols (56 °C-30 min, 60 °C-60 min and 92 °C-15 min) on SARS-CoV-2 using (i) infected cell culture supernatant, (ii) virus-spiked human sera (iii) and nasopharyngeal samples according to the recommendations of the European norm NF EN 14476-A2. Regardless of the protocol and the type of samples, a 4 Log10 TCID50 reduction was observed. However, samples containing viral loads > 6 Log10 TCID50 were still infectious after 56 °C-30 min and 60 °C-60 min, although infectivity was < 10 TCID50. The protocols 56 °C-30 min and 60 °C-60 min had little influence on the RNA copies detection, whereas 92 °C-15 min drastically reduced the limit of detection, which suggests that this protocol should be avoided for inactivation ahead of molecular diagnostics. Lastly, 56 °C-30 min treatment of serum specimens had a negligible influence on the results of IgG detection using a commercial ELISA test, whereas a drastic decrease in neutralizing titers was observed.


Assuntos
Betacoronavirus , Contenção de Riscos Biológicos/métodos , Infecções por Coronavirus/virologia , Pneumonia Viral/virologia , Testes Sorológicos/métodos , Inativação de Vírus , Anticorpos Neutralizantes/imunologia , Betacoronavirus/imunologia , Contenção de Riscos Biológicos/normas , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/prevenção & controle , Ensaio de Imunoadsorção Enzimática , Temperatura Alta , Humanos , Testes de Neutralização , Pandemias/prevenção & controle , Pneumonia Viral/diagnóstico , Pneumonia Viral/prevenção & controle , Testes Sorológicos/normas
2.
Viruses ; 12(6)2020 06 08.
Artigo em Inglês | MEDLINE | ID: mdl-32521706

RESUMO

Clinical samples collected in coronavirus disease 19 (COVID-19), patients are commonly manipulated in biosafety level 2 laboratories for molecular diagnostic purposes. Here, we tested French norm NF-EN-14476+A2 derived from European standard EN-14885 to assess the risk of manipulating infectious viruses prior to RNA extraction. SARS-CoV-2 cell-culture supernatant and nasopharyngeal samples (virus-spiked samples and clinical samples collected in COVID-19 patients) were used to measure the reduction of infectivity after 10 minute contact with lysis buffer containing various detergents and chaotropic agents. A total of thirteen protocols were evaluated. Two commercially available formulations showed the ability to reduce infectivity by at least 6 log 10, whereas others proved less effective.


Assuntos
Betacoronavirus/efeitos dos fármacos , Infecções por Coronavirus/virologia , Pneumonia Viral/virologia , Inativação de Vírus/efeitos dos fármacos , Animais , Betacoronavirus/genética , Betacoronavirus/isolamento & purificação , Betacoronavirus/fisiologia , Técnicas de Cultura de Células/métodos , Chlorocebus aethiops , Contenção de Riscos Biológicos/métodos , Contenção de Riscos Biológicos/normas , Humanos , Nasofaringe/virologia , Pandemias , RNA Viral/isolamento & purificação , Manejo de Espécimes/métodos , Células Vero , Carga Viral/métodos
3.
J Pak Med Assoc ; 70(Suppl 3)(5): S48-S51, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32515375

RESUMO

COVID-19 poses a great challenge to clinical and diagnostic services around the world. The need of biosafety practices can never be emphasised more than under current circumstances. The four pillars of biosafety namely, leadership, standard operating procedures, personal protective equipment (PPE) and engineering controls must be employed for effective and safe practices in the clinical setting in general and laboratory settings in particular. Risk assessment must be carried out before meeting up the diagnostic challenge for COVID-19 and essential biorisk management measures are required to be taken. In our resource-poor settings, we need to adapt safe but cost-effective and improvised solutions to ensure safe handling of clinical samples from COVID-19 patients in the laboratories. The correct use of PPE and their suitable alternatives are available for selection and use. Disinfection of the lab areas and safe disposal of the clinical samples from such patients is also of paramount importance.


Assuntos
Betacoronavirus , Técnicas de Laboratório Clínico/normas , Contenção de Riscos Biológicos , Infecções por Coronavirus , Pandemias , Pneumonia Viral , Contenção de Riscos Biológicos/métodos , Contenção de Riscos Biológicos/normas , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/prevenção & controle , Humanos , Controle de Infecções/normas , Laboratórios/normas , Pandemias/prevenção & controle , Equipamento de Proteção Individual , Pneumonia Viral/diagnóstico , Pneumonia Viral/prevenção & controle , Medição de Risco
4.
Zhejiang Da Xue Xue Bao Yi Xue Ban ; 49(2): 170-177, 2020 May 25.
Artigo em Chinês | MEDLINE | ID: mdl-32391660

RESUMO

Coronavirus disease 2019 (COVID-19) is a grade B infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In pace with the spreading of the disease, biosafety risk of the biological specimen preservation in biobanks has been significantly increased and biosafety protection during biological specimen preservation become increasingly important. According to the related national rules and the corresponding guidelines of Chinese Medical Association, this paper introduced the etiology about SARS-CoV-2, epidemiology about COVID-19, and the biosafety protection principles of individuals and biological specimen storage places in the process of personal protection, protection of collection, transport, handling, preservation, detection, post-detection disposal and emergencies of biological specimen. Emphasized to carry out a strict biosafety-risk assessment on biological specimen basing on virus load information, infectivity, and sample type (possible contact transmission, aerosol transmission, and fecal oral transmission).


Assuntos
Contenção de Riscos Biológicos , Infecções por Coronavirus , Pandemias , Pneumonia Viral , Manejo de Espécimes , Betacoronavirus/isolamento & purificação , Contenção de Riscos Biológicos/normas , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/transmissão , Humanos , Pandemias/prevenção & controle , Pneumonia Viral/epidemiologia , Pneumonia Viral/prevenção & controle , Pneumonia Viral/transmissão , Prevalência , Medição de Risco , Manejo de Espécimes/normas
5.
Recurso na Internet em Espanhol | LIS - Localizador de Informação em Saúde | ID: lis-LISBR1.1-47220

RESUMO

La salud humana está relacionada íntimamente con la salud del resto de los integrantes de los ecosistemas, de tal modo que las alteraciones en la integridad del mundo físico y del biota vegetal-animal, tienen su correlato en la salud humana y viceversa... Recomendaciones de bioseguridad para el equipo de salud, medidas protectivas para disminuir el riesgo a que se ve expuesto el personal de salud. Incluye un link para conocer los casos en el mundo en Tiempo Real.


Assuntos
Betacoronavirus/patogenicidade , Infecções por Coronavirus , Pneumonia Viral , Surtos de Doenças , Doenças Transmissíveis Emergentes , Contenção de Riscos Biológicos/normas , Pessoal de Saúde ,
6.
Cancer Cytopathol ; 128(5): 317-320, 2020 May.
Artigo em Inglês | MEDLINE | ID: mdl-32259373

RESUMO

The 2019 coronavirus pandemic, which started in Wuhan, China, spread around the globe with dramatic and lethal effects. From the initial Chinese epicenter, the European diaspora taxed the resources of several countries and especially those of Italy, which was forced into a complete social and economic shutdown. Infection by droplets contaminating hands and surfaces represents the main vehicle of diffusion of the virus. The common and strong efforts to contain the pandemic have relevant effects on the management of samples from histopathology laboratories. The current commentary reports and focuses on the protocols and guidelines in use at a large tertiary Italian hospital that accordingly are proposed for adoption in Italian laboratories as a potential model for national guidelines for the coronavirus emergency.


Assuntos
Contenção de Riscos Biológicos/métodos , Infecções por Coronavirus/patologia , Técnicas Citológicas/métodos , Transmissão de Doença Infecciosa do Paciente para o Profissional/prevenção & controle , Pneumonia Viral/patologia , Contenção de Riscos Biológicos/normas , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/transmissão , Infecções por Coronavirus/virologia , Técnicas Citológicas/normas , Humanos , Controle de Infecções/métodos , Controle de Infecções/normas , Itália , Pandemias , Pneumonia Viral/epidemiologia , Pneumonia Viral/transmissão , Pneumonia Viral/virologia
8.
J Am Soc Cytopathol ; 9(3): 202-211, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32284276

RESUMO

The coronavirus disease 2019 (COVID-19) is a pandemic caused by the SARS-CoV-2 virus. The infection has predominantly respiratory transmission and is transmitted through large droplets or aerosols, and less commonly by contact with infected surfaces or fomites. The alarming spread of the infection and the severe clinical disease that it may cause have led to the widespread institution of social distancing measures. Because of repeated exposure to potentially infectious patients and specimens, health care and laboratory personnel are particularly susceptible to contract COVID-19. This review paper provides an assessment of the current state of knowledge about the disease and its pathology, and the potential presence of the virus in cytology specimens. It also discusses the measures that cytology laboratories can take to function during the pandemic, and minimize the risk to their personnel, trainees, and pathologists. In addition, it explores potential means to continue to educate trainees during the COVID-19 pandemic.


Assuntos
Biologia Celular/tendências , Serviços de Laboratório Clínico/normas , Infecções por Coronavirus/patologia , Infecções por Coronavirus/prevenção & controle , Pandemias/prevenção & controle , Pneumonia Viral/patologia , Pneumonia Viral/prevenção & controle , Manejo de Espécimes/normas , Betacoronavirus/patogenicidade , Serviços de Laboratório Clínico/tendências , Contenção de Riscos Biológicos/normas , Infecções por Coronavirus/transmissão , Infecções por Coronavirus/virologia , Humanos , Pneumonia Viral/transmissão , Pneumonia Viral/virologia , Segurança , Manejo de Espécimes/tendências
10.
Guatemala; MSPAS. Departamento de Epidemiología-Dirección General del SIAS; 8 mar 2020. 4 p. (CIE 10 U07.1).
Não convencional em Espanhol | LILACS, LIGCSA | ID: biblio-1096262

RESUMO

El documento contiene lineamientos para fortalecer el sistema de vigilancia en puertos, aeropuerto y puestos fronterizos para detectar oportunamente casos de Covid-19


Assuntos
Humanos , Pneumonia Viral/prevenção & controle , Infecções por Coronavirus/prevenção & controle , Controle Sanitário de Aeroportos e Aeronaves , Monitoramento Epidemiológico , Medidas de Segurança/normas , Contenção de Riscos Biológicos/normas , Controle Sanitário de Fronteiras , Guatemala
11.
Guatemala; MSPAS, Coordinación de Hospitales; 27 mar 2020. graf.
Não convencional em Espanhol | LILACS, LIGCSA | ID: biblio-1096347

RESUMO

Este documento da orientación provisional procura fortalecer la respuesta de los servicios hospitalarios ante la posibilidad de tener casos en el país de COVID-19, especialmente en la parte de prevención de la transmisión a del fortalecimiento de las precauciones estándar para la prevención y control de infecciones, con énfasis en el lavado de manos y el uso de equipo protección personal por parte del personal de salud. Además, provee orientaciones para organizar los servicios hospitalarios para adecuar áreas de aislamiento, cuidados intermedios y áreas de triage. El documento también orienta para la proyección de costos de insumos: Material medico quirúrgico, medicamentos, recursos humanos, entre otros como preparación para la respuesta (AU).


Assuntos
Humanos , Organização e Administração/normas , Pneumonia Viral/diagnóstico , Infecções por Coronavirus/diagnóstico , Betacoronavirus , Assistência ao Paciente/métodos , Cadáver , Preparações Farmacêuticas/economia , Contenção de Riscos Biológicos/normas , Sistema de Vigilância Sanitária , Programa de Controle de Infecção Hospitalar , Guatemala , Resíduos de Serviços de Saúde/prevenção & controle
12.
J Histotechnol ; 43(2): 102-104, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32116147

RESUMO

The 2019 Coronavirus epidemic, provisionally called 2019-nCoV, was first identified in Wuhan, China, in persons exposed to a seafood or wet market. There is an international push to contain the virus and prevent its spread. It is feasible that potentially infectious samples may be received in histopathology laboratories for diagnosis. This technical note presents disinfection procedures and histotechnology processes that should alleviate the risk of infection to laboratory staff. Using data obtained from similar coronaviruses, e.g. severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), experts are confident that 70% ethanol and 0.1% sodium hypochlorite should inactivate the virus. Formalin fixation and heating samples to 56oC, as used in routine tissue processing, were found to inactivate several coronaviruses and it is believed that 2019-nCoV would be similarly affected.


Assuntos
Betacoronavirus , Contenção de Riscos Biológicos/métodos , Infecções por Coronavirus , Desinfecção/métodos , Pandemias , Patologia Clínica/métodos , Pneumonia Viral , Contenção de Riscos Biológicos/normas , Desinfecção/normas , Técnicas Histológicas/normas , Humanos , Laboratórios/normas , Patologia Clínica/normas
13.
Washington; Organización Panamericana de la Salud; feb. 1, 2020. 5 p.
Não convencional em Espanhol | LILACS | ID: biblio-1096511

RESUMO

Los coronavirus son un grupo de virus ARN altamente diversos de la familia Coronaviridae que se dividen en 4 géneros: alfa, beta, gamma y delta, y que causan enfermedades de leves a graves en humanos y animales (1) (2) (3). Existen coronavirus humanos endémicos como los alfacoronavirus 229E y NL63 y los betacoronavirus OC43 y HKU1 que pueden causar enfermedades de tipo influenza o neumonía en humanos (1) (3). Sin embargo, dos coronavirus zoonóticos que causan enfermedades graves en humanos han emergido: el coronavirus del Síndrome respiratorio agudo grave (SARS-CoV) en 2002-2003 y el coronavirus del Síndrome respiratorio de Oriente Medio (MERS-CoV) (4) (5). En enero de 2020, el agente etiológico responsable de un grupo de casos de neumonía grave en Wuhan, China, fue identificado como un nuevo betacoronavirus (2019-nCoV), distinto del SARS-CoV y MERS-CoV (6) (7). La secuencia genómica completa de este nuevo agente está disponible y se han desarrollado diferentes protocolos de detección, aunque aún no se han validado por completo. Sin embargo, a la luz de la posible introducción de un caso sospechoso relacionado con el 2019-nCoV en la Región de las Américas, la Organización Panamericana de la Salud / Organización Mundial de la Salud (OPS / OMS) recomienda a los Estados Miembros garantizar su identificación oportuna, el envío de las muestras a laboratorios Nacionales y de referencia y la implementación del protocolo de detección molecular para 2019-nCoV, según la capacidad del laboratorio.


Assuntos
Humanos , Pneumonia Viral/virologia , Reação em Cadeia da Polimerase/métodos , Infecções por Coronavirus/diagnóstico , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/virologia , Contenção de Riscos Biológicos/normas , Pandemias/prevenção & controle , Betacoronavirus/isolamento & purificação , China/epidemiologia
14.
Guatemala; MSPAS, Laboratorio Nacional de Salud/Centro Nacional de Influenza (NIC); 30 ene 2020. 16 p. graf.
Não convencional em Espanhol | LILACS, LIGCSA | ID: biblio-1096331

RESUMO

Brinda los lineamientos generales para la toma de muestra, conservación y transporte, para el diagnóstico de virus respiratorios y su posterior envío al Centro Nacional de Influenza (NIC) del Laboratorio Nacional de Salud; establecidos a nivel nacional así como la bioseguridad en la toma de las muestras de un paciente sospechoso


Assuntos
Humanos , Pneumonia Viral/diagnóstico , Manejo de Espécimes/métodos , Infecções por Coronavirus/diagnóstico , Técnicas de Laboratório Clínico/normas , Nasofaringe/virologia , Contenção de Riscos Biológicos/normas , Técnicas e Procedimentos Diagnósticos/normas , Equipamento de Proteção Individual , Guatemala
15.
Artigo em Espanhol | LILACS | ID: biblio-1087828

RESUMO

El SARS-Cov-2 es un coronavirus productor de la enfermedad COVID-19. Esta inició en Wuhan, capital de la provincia Hubei, China. En menos de cuatro meses la enfermedad se dispersó por el mundo, lo que dio origen a miles de muertes. La Organización Mundial de la Salud (OMS) la ha declarado pandemia. La humanidad está consternada, múltiples gobiernos han obligado al aislamiento total, con éxito variable debido a la negligencia de parte de la comunidad. En muchas ciudades las instituciones y el personal sanitario no son suficientes para atender la catástrofe. El aislamiento es la única estrategia eficaz para detener el crecimiento logarítmico de COVID-19. El motivo científico del aislamiento es que más del 60 % de los contagios surgen de personas asintomáticas. La enfermedad no solo produce síntomas respiratorios. El SARS-Cov-2, además, puede producir náuseas, dolor abdominal, vómito, diarrea, anosmia y ageusia. El 50% de los infectados pueden tener síntomas digestivos, que incluso preceden a los respiratorios. La ruta fecal-oral trasmite el virus, aún sin diarrea. En las unidades de endoscopia están todas las formas de contagio: aerosoles (vómitos, arcadas, eructos, flatos), materia fecal, contacto estrecho, contaminación del ambiente. Se deben suspender todas las endoscopias programadas para diagnóstico. Solo deben realizarse las urgentes y terapéuticas. Todo el personal de endoscopia debe tener medidas de protección estrictas. El paciente debe saber que en la sala de endoscopia puede contagiarse, con constancia en el consentimiento informado. Debe contactarse al paciente posendoscopia vía telefónica a los días 7 y 14 para indagar sobre todos los síntomas mencionados.(AU)


SARS-CoV-2 is the coronavirus which produces the dreaded COVID-19. Starting in Wuhan, the capital of China's Hubei province, it has spread it spread throughout the world in less than four months and has caused thousands of deaths. The WHO has declared it to be a pandemic. Humanity is shocked, and many governments have imposed total isolation. It has had varying success due to community negligence. In many cities, institutions and health personnel have not successfully managed this catastrophe. Isolation is the only effective strategy to stop the logarithmic growth of COVID 19. The scientific reason for isolation is that more than 60 % of infections arise from asymptomatic people. SARS-CoV-2 not only produces respiratory symptoms but can also cause nausea, abdominal pain, vomiting, diarrhea, anosmia and ageusia. Fifty percent of those infected may have digestive symptoms which may even precede respiratory symptoms. The fecal-oral route can transmit the virus even when there is no diarrhea. All forms of contagion are found in endoscopy units: aerosols from vomiting, retching, bel-ching, and flatus; fecal matter, close contact, and contamination of the environment. All diagnostic endoscopies should be discontinued. Only urgent and therapeutic endoscopy should be performed. All endoscopy personnel must have strict protection measures. Each patient should be informed, and sign an informed consent form, that the virus can be spread within the endoscopy room. After performance of endoscopy, the patient should be contacted by phone on days 7 and 14 to inquire about all symptoms mentioned.(AU)


Assuntos
Humanos , Infecções por Coronavirus/prevenção & controle , Infecções por Coronavirus/transmissão , Endoscopia/normas , Isolamento de Pacientes , Contenção de Riscos Biológicos/normas , Coliformes/prevenção & controle
16.
Health Secur ; 17(5): 372-383, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31593511

RESUMO

Laboratory-acquired infections (LAIs), an occupational illness, are defined as all infections acquired through laboratory or laboratory-related activities. A report published in 1898 described an LAI resulting from Corynebacterium diphtheriae being transmitted through mouth pipetting. Despite all efforts, LAIs continue, especially in developing countries like Pakistan, which has been fighting to curb many infectious diseases. As reflected in the published literature, the biosafety culture is severely lacking in many laboratories, and there are no data available from Pakistan on LAIs. Our objective was to ascertain the frequency and rate of LAIs in various labs with versatile portfolios in relation to biosafety and biosecurity practices in Karachi. Ours is a descriptive multicenter cross-sectional study conducted in 30 laboratories located in Karachi from November 2017 to April 2018. Data were collected from laboratories including the university hospital labs, research labs, animal labs, and biomedical labs. Out of 30 facilities, half (n = 15) were clinical/biomedical laboratories, 16.6% (n = 5) were university hospital laboratories, 26.6% (n = 8) were R&D laboratories, and 6.6% (n = 2) were animal laboratories. Needle stick was found to be the most common injury, followed by animal bite/scratch, cut on mucous membrane, falling of personnel, and burn injury.


Assuntos
Contenção de Riscos Biológicos/métodos , Contenção de Riscos Biológicos/normas , Infecção Laboratorial/epidemiologia , Doenças Profissionais/epidemiologia , Estudos Transversais , Fidelidade a Diretrizes , Guias como Assunto , Humanos , Laboratórios/classificação , Paquistão/epidemiologia , Prevalência , Medição de Risco , Gestão de Riscos , Inquéritos e Questionários
17.
Am J Health Syst Pharm ; 76(9): 599-607, 2019 Apr 17.
Artigo em Inglês | MEDLINE | ID: mdl-31361829

RESUMO

PURPOSE: This study investigates the use of a canopy-connected recirculating class II type A2 biological safety cabinet (BSC) as an alternative to the B2 when preparing volatile, sterile compounded preparations. Selection of the appropriate BSC for processes that use subgram levels of volatile chemicals is difficult due to a lack of quantitative containment evidence by cabinet type. There is a perception that hazardous compounding must be done in a B2 cabinet due to the potential for vapors, and this study seeks to challenge that perception. METHODS: In total, 5 tests, 3 prequalification tests and 2 containment capability tests, were conducted on a single cabinet of each type at sterile compounding pharmacies. Prequalification tests were performed to verify that each BSC was operating properly. Each cabinet was certified to NSF-ANSI 49-2016, particle counted per ISO 14644-1:1999, and subjected to a qualitative video smoke study. Once these tests confirmed the expected working conditions, 2 containment capability tests were conducted. The containment testing included tracer gas testing per ASHRAE 110:2016 section 8.1.1 through 8.1.13, and cyclophosphamide sampling during sterile compounding of the drug material. RESULTS: Both cabinets passed all the prequalification tests. During the ASHRAE tracer gas testing the A2 cabinet was able to contain a tracer gas 92% to 160% as effectively as the B2 cabinet depending on the position of the gas ejection. During sterile compounding the airborne cyclophosphamide sampling captured samples of less than 1.0 ng at all locations for both the A2 and B2 cabinets. CONCLUSION: The data generated from this study demonstrate that use of an A2 for hazardous compounding can provide a comparable level of safety for the environment, users, and product while having less stringent airflow requirements relative to a B2. The simpler requirements for an A2 make them an appealing alternative as they have the potential to reduce the overall operating costs associated with a compounding pharmacy while maintaining safe levels of containment.


Assuntos
Contenção de Riscos Biológicos/instrumentação , Composição de Medicamentos/instrumentação , Assistência Farmacêutica/normas , Antineoplásicos Alquilantes/análise , Contenção de Riscos Biológicos/normas , Ciclofosfamida/análise , Composição de Medicamentos/normas , Contaminação de Equipamentos/prevenção & controle , Substâncias Perigosas/análise , Humanos
18.
Rev. Asoc. Esp. Espec. Med. Trab ; 28(2): 91-108, jun. 2019. tab, graf
Artigo em Espanhol | IBECS | ID: ibc-186001

RESUMO

Objetivo: comparar la evaluación del nivel del riesgo biológico de los métodos Biogaval y GTC 45. Métodos: estudio descriptivo observacional de corte transversal aplicado a una muestra de 24 laboratorios. Se aplicó analisis correlacional de puntuaciones típicas. Resultados: el 95% (n = 23) de los laboratorios en Límite de Acción Biológica y el 4,2% (n = 1) en Nivel de Acción Biológica, según Biogaval; y el 41,6% (n = 10) en situación crítica y el 58,3% (n = 14) de los laboratorios debe adoptar medidas de control inmediato, según GTC-45. Se encontró correlación positiva perfecta (Rho=1.00) en las variables cumplimiento de medidas higiénicas/nivel de deficiencia, así como nivel de exposición/frecuencia de realización de tareas; muy al contrario, la determinación del nivel de incidencia/nivel de probabilidad no presentaron una correlación significativa (Rho = 0.103). No existe una correlación significativa (Rho = 0.468) entre el método Biogaval y el método GTC 45. Discusión: se hace necesario proponer un método dirigido hacia los microorganismos a riesgo y acorde con la normatividad colombiana


Objective: to compare the evaluation of the biological risk level of the Biogaval and GTC 45 methods. Methods: an observational cross-sectional descriptive study applied to a sample of 24 laboratories. Correlation analysis of typical scores was applied.Results:95% (n = 23) of the laboratories in Biological Action Limit and 4.2% (n = 1) in the Biological Action Level, according to Biogaval; and 41.6% (n = 10) in a critical situation and 58.3% (n = 14) of the laboratories must adopt immediate control measures, according to GTC-45. We found a perfect positive correlation (Rho = 1.00) in the variables compliance with hygienic measures / level of deficiency, as well as level of exposure / frequency of completion of tasks; On the contrary, the determination of the level of incidence / level of probability did not how a significant correlation (Rho = 0.103). There is no significant correlation (Rho = 0.468) between the Biogaval method and the GTC 45 method. Discussion:it is necessary to propose a method aimed at microorganisms at risk and in accordance with Colombian regulations


Assuntos
Humanos , Medição de Risco , Exposição Ocupacional , Laboratórios/normas , Contenção de Riscos Biológicos/métodos , Contenção de Riscos Biológicos/normas , Estudos Transversais , Colômbia
19.
Nurs Clin North Am ; 54(2): 169-180, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-31027659

RESUMO

The 2014 to 2016 Ebola outbreak response resulted in many lessons learned about biocontainment patient care, leading to enhanced domestic capabilities for highly infectious and hazardous communicable diseases. However, additional opportunities for improvement remain. The article identifies and describes key considerations and challenges for laboratory analysis, clinical management, transportation, and personnel management during the care of patients infected with Ebola or other special pathogens. Dedication to maintaining preparedness enables biocontainment patient care teams to perform at the highest levels of safety and confidence.


Assuntos
Contenção de Riscos Biológicos/normas , Surtos de Doenças/prevenção & controle , Guias como Assunto , Doença pelo Vírus Ebola/diagnóstico , Doença pelo Vírus Ebola/terapia , Medidas de Segurança/normas , África Ocidental , Humanos , Estados Unidos
20.
Chemosphere ; 221: 708-726, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30677729

RESUMO

The number of biosafety evaluation studies of nanoparticles (NPs) using different biological models is increasing with the rapid development of nanotechnology. Thus far, nematode Caenorhabditis elegans (C. elegans), as a complete model organism, has become an important in vivo alternative assay system to assess the risk of NPs, especially at the environmental level. According to results of qualitative and quantitative analyses, it can be concluded that studies of nanoscientific research using C. elegans is persistently growing. However, the comprehensive conclusion and analysis of toxic effects of NPs in C. elegans are limited and chaotic. This review focused on the effects, especially sublethal ones, induced by NPs in C. elegans, including the development, intestinal function, immune response, neuronal function, and reproduction, as well as the underlying mechanisms of NPs causing these effects, including oxidative stress and alterations of several signaling pathways. Furthermore, we presented some factors that influence the toxic effects of NPs in C. elegans. The advantages and limitations of using nematodes in the nanotoxicology study were also discussed. Finally, we predicted that the application of C. elegans to assess long-term impacts of metal oxide NPs in the ecosystem would become a vital part of the nanoscientific research field, which provided an insight for further study.


Assuntos
Caenorhabditis elegans/efeitos dos fármacos , Contenção de Riscos Biológicos/normas , Nanopartículas Metálicas/toxicidade , Animais , Ecossistema , Estresse Oxidativo/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA